Name of License: Intent to Grant an Exclusive License for U.S. Government-Owned Invention
Summary: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.
Dates: April 18, 2022 (Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication)
Address: Commander, U.S. Army Medical Research and Development Command, ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite 227, Fort Detrick, MD 21702-5012.
For Further Information Contact: Dr. Paul Michaels, Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.
Supplementary Information: In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license to United States Patent 10,434,167 issued on October 8, 2019, entitled “Non-Toxic Adjuvant Formulation Comprising a Monophosphoryl Lipid A (MPLA)-Containing Liposome Composition and a Saponin” to Pfizer having its principal place of business at 235 E 42nd Street, New York, New York 10017.
Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications (see ADDRESSES).